Cytokine release syndrome (CRS) is a reaction that can happen when the immune system becomes overly activated — particularly after certain myeloma treatments like CAR T-cell therapy or bispecific antibodies (such as teclistamab).
When T-cells are activated, they release large amounts of cytokines, which are chemical Show Full Answer
Cytokine release syndrome (CRS) is a reaction that can happen when the immune system becomes overly activated — particularly after certain myeloma treatments like CAR T-cell therapy or bispecific antibodies (such as teclistamab).
When T-cells are activated, they release large amounts of cytokines, which are chemical messengers in the immune system. When too many flood the body at once, they can start damaging healthy tissues. Common symptoms of CRS include:
- Fever and chills
- Breathing difficulties
- Low blood pressure
- Headache
- Confusion
- Muscle and joint pain
In most cases, CRS is mild and manageable. However, in severe cases it can lead to organ failure and become life-threatening, so it's taken very seriously by medical teams. The good news is that treatments are available to manage CRS, including a medication called tocilizumab and corticosteroids. Myeloma treatments that carry a CRS risk are only given at specially certified centers where staff are trained to spot and treat it quickly.
Always let your care team know right away if you experience any of these symptoms after a treatment.
August 24
Join
Your Privacy Choices
